Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC

Bone Marrow Transplantation volume 58, pages 1331–1338 (2023)Cite this article

Subjects

Abstract

We report the results from a multicentre retrospective study of 220 adult patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) for therapy-related acute myeloid leukaemia (t-AML). Median age at t-AML diagnosis was 56 years, with a prior history of haematological (45%) or breast (34%). Median time from cytotoxic exposure to t-AML diagnosis was 54.7 months. At transplant, around 20% of patients had measurable residual disease and 3% of patients were not in complete remission. The median follow-up was 21.4 months (Q1–Q3, 5.9–52.8). At 12 months, overall survival (OS), event-free survival (EFS), and graft-versus-host-disease (GVHD)-free-relapse-free survival (GRFS) were 60.7% (95% CI 54.6–67.5), 52.8% (95% CI 46.5–68.4), and 44.1% (95% CI 37.6–51.8), respectively. At 5 years, OS, EFS, and GRFS were 44.1% (95% CI 37.4–52.1), 40.4% (95% CI 33.9–48.1), and 35.3% (95% CI 28.8–43.3), respectively. At last follow-up, 44% of patients were in complete remission (n = 96) and transplant-related mortality accounted for 21% of all deaths (n = 119). Multivariable analysis revealed that uncontrolled t-AML at transplant was associated with lower EFS (HR 1.94, 95% CI 1.0–3.7, p = 0.041). In conclusion, alloHSCT for t-AML shows encouraging results and offers additional opportunity with the emergence of novel pre-graft therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Overall survival after transplant within the entire cohort and subgroups of patients.
Fig. 2: Event-free survival after transplant within the entire cohort and subgroups of patients.
Fig. 3: Graft-versus-host disease-free relapse-free survival within the entire cohort.

Similar content being viewed by others

Data availability

All data supporting this article are provided in the manuscript (Tables 1–4; Figs. 1, 2 and 3; Supplementary Data 1 and 2).

References

  1. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. The role of TP53 mutations in the origin and evolution of therapy-related AML. Nature. 2015;518:552–5.

    Article  CAS  PubMed  Google Scholar 

  3. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5:943–55.

    Article  CAS  PubMed  Google Scholar 

  4. Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology. 2007;2007:453–9.

    Article  Google Scholar 

  5. Nenova I, Grudeva-Popova J. Carcinogenic potential of antitumor therapies - is the risk predictable? J BUON. 2017;22:1378–84.

    PubMed  Google Scholar 

  6. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013;121:2996–3004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Borthakur G, Estey EE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep. 2007;9:373–7.

    Article  CAS  PubMed  Google Scholar 

  8. Cancer Survivorship --- United States, 1971–2001. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5324a3.htm (accessed 20 Sep2021).

  9. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–85.

    Article  PubMed  Google Scholar 

  10. Nilsson C, Linde F, Hulegårdh E, Garelius H, Lazarevic V, Antunovic P, et al. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica. 2022. https://doi.org/10.3324/haematol.2022.281233.

  11. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. JCO. 2015;33:3641–9.

    Article  Google Scholar 

  12. Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013;26:309–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Derolf ÅR, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–14.

    Article  PubMed  Google Scholar 

  14. Nampoothiri RV, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, et al. Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2022;15:27–35.

    CAS  PubMed  Google Scholar 

  15. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

    Article  CAS  PubMed  Google Scholar 

  16. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  PubMed  PubMed Central  Google Scholar 

  17. McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng G-S, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med. 2020;172:229.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021;27:923.e1–923.e12.

    Article  CAS  PubMed  Google Scholar 

  19. Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577–90.

    Article  PubMed  Google Scholar 

  20. Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, et al. Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: a report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94:431–8.

    Article  CAS  PubMed  Google Scholar 

  21. Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, et al. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leuk Res. 2015;39:828–34.

    Article  CAS  PubMed  Google Scholar 

  22. Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, et al. Allogeneic hematopoietic stem cell transplantation for adolescents and young adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23:1515–22.

    Article  PubMed  Google Scholar 

  23. Goyal SD, Zhang M-J, Wang H-L, Akpek G, Copelan EA, Freytes C, et al. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transpl. 2015;50:1057–62.

    Article  CAS  Google Scholar 

  24. Yokohama Cooperative Study Group for Hematology (YACHT), Ando T, Fujisawa S, Teshigawara H, Ogusa E, Ishii Y, et al. Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. Int J Hematol. 2019;109:673–83.

    Article  Google Scholar 

  25. Schmaelter A-K, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Salas MQ, Chen S, Lam W, Pasic I, Gerbitz A, Michelis FV, et al. Less is more: superior graft-versus-host disease-free/relapse-free survival with reduced-intensity conditioning and dual T cell depletion in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26:1511–9.

    Article  CAS  PubMed  Google Scholar 

  27. Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transpl. 2020;55:224–32.

    Article  CAS  Google Scholar 

  28. Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for blood and bone marrow transplantation study. Biol Blood Marrow Transplant. 2018;24:1406–14.

    Article  PubMed  Google Scholar 

  29. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170:574–83.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Jullien M, Orvain C, Berceanu A, Couturier M, Guillaume T, Peterlin P, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide. Cancer Med. 2021;10:7194–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, et al. Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity/age index in recipients of allogeneic hematopoietic stem cell transplantation from alternative graft sources. Biol Blood Marrow Transplant. 2019;25:1045–52.

    Article  PubMed  Google Scholar 

  33. D’Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, et al. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:629–38.

    Article  PubMed  Google Scholar 

  34. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61:288–97.

    Article  CAS  PubMed  Google Scholar 

  35. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid. Leuk JCO. 2018;36:2684–92.

    Article  CAS  Google Scholar 

  36. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.

    Article  CAS  PubMed  Google Scholar 

  37. Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’hématologie clinique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France

    Gaëlle Rey, Emilie Chalayer, Jérôme Cornillon & Emmanuelle Tavernier

  2. Département Universitaire de Recherche et d’Enseignement, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France

    Elisabeth Daguenet

  3. Unité de Recherche Clinique Innovation Pharmacologique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France

    Paul Bonjean

  4. Institut Paoli Calmette, Marseille, France

    Raynier Devillier

  5. Hôpital Saint Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, France

    Nathalie Fegueux

  6. Centre Hospitalier Universitaire Haut-Lévêque Magellan, Bordeaux, France

    Edouard Forcade

  7. Hôpital Claude Hurriez, Centre Hospitalier Universitaire de Lille, Lille, France

    Micha Srour

  8. Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France

    Patrice Chevallier

  9. Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France

    Marie Robin

  10. Hôpital Necker, Paris, France

    Felipe Suarez

  11. Institut Gustave Roussy, Villejuif, France

    Jean-Baptiste Micol

  12. Hôpital Lyon Sud, Centre Hospitalier Universitaire de Lyon, Lyon, France

    Hélène Labussière-Wallet

  13. Centre Hospitalier Universitaire Hautepierre, Strasbourg, France

    Karin Bilger

  14. Centre Hospitalier Universitaire Jean Minjoz, Besançon, France

    Etienne Daguindau

  15. Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France

    Jacques-Olivier Bay & Amandine Fayard

  16. Centre Hospitalier Universitaire de Grenoble, Grenoble, France

    Claude-Eric Bulabois

  17. Hôpital Pitié-Salpêtrière, Paris, France

    Stéphanie Nguyen-Quoc

  18. Hôpital Saint-Antoine, Paris, France

    Alexis Genthon

  19. Centre Hospitalier Universitaire d’Angers, Angers, France

    Corentin Orvain

  20. Centre Hospitalier Universitaire Dupuytren, Limoges, France

    Pascal Turlure

  21. Hôpital de l’Archet, Centre Hospitalier Universitaire de Nice, Nice, France

    Michael Loschi

  22. Cliniques Universitaires St. Luc, Brussels, Belgium

    Xavier Poiré

  23. Centre Hospitalier Universitaire Augustin Morvan, Brest, France

    Gaëlle Guillerm

  24. CHU of Liège and University of Liège, Liège, Belgium

    Yves Beguin

  25. Hôpital Jean Bernard, Poitiers, France

    Natacha Maillard

  26. Centre Hospitalier Universitaire de Rennes, Rennes, France

    Jean-Baptiste Mear

Authors
  1. Gaëlle Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth Daguenet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Bonjean
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raynier Devillier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nathalie Fegueux
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edouard Forcade
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Micha Srour
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patrice Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marie Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Felipe Suarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jean-Baptiste Micol
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hélène Labussière-Wallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Karin Bilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Etienne Daguindau
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jacques-Olivier Bay
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Amandine Fayard
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Claude-Eric Bulabois
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Stéphanie Nguyen-Quoc
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Alexis Genthon
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Corentin Orvain
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Pascal Turlure
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Michael Loschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Xavier Poiré
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Gaëlle Guillerm
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Yves Beguin
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Natacha Maillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Jean-Baptiste Mear
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Emilie Chalayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Jérôme Cornillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Emmanuelle Tavernier
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualisation, ET; Methodology, GR, ED, ET; Patients care, GR, RD, NF, EF, MS, PC, MR, FS, JBM, HLW, KB, ED, JOB, AF, CEB, SNQ, AG, CO, PT, ML, XP, GG, YB, NM, JBM, EC, JC, ET; Collected the data, GR, ED, RD, NF, EF, MS, PC, MR, FS, JBM, HLW, KB, ED, JOB, AF, CEB, SNQ, AG, CO, PT, ML, XP, GG, YB, NM, JBM, EC, JC, ET; Analysed data, GR, ED, PB, ET; Writing – original draft, GR, ED, ET; Review and editing, all the authors.

Corresponding author

Correspondence to Emmanuelle Tavernier.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rey, G., Daguenet, E., Bonjean, P. et al. Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC. Bone Marrow Transplant 58, 1331–1338 (2023). https://doi.org/10.1038/s41409-023-02082-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02082-5

Search

Advanced search

Quick links